Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...